Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
Trusted, unrivalled expertise.
Contact us to discuss your requirements.
Streamlining patient access to safe, financially sustainable and innovative medicines.
Updated manuals for methods, processes and topic selection.
Accelerating our efforts to deliver innovation to the health and care system.
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Ensuring new technologies are clinically effective and offer economic value.
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Guidance on measurements and tests used to evaluate a patient's condition.
Guidance on medical technologies put forward to NICE by manufacturers.
Guidance on new and existing medicines and treatments in the NHS.
Guidance on the use of highly specialised medicines and treatments.
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Learn about the information we produce.
Understand how decisions are made:
Comment on draft guidance:
Be part of a guidance committee:
Help develop our products:
Putting you at the heart of our work:
You are here:
A list of downloadable documents created during development.
Consultation comments and responses (PDF 452 KB)
Equality impact assessment (PDF 130 KB)
Diagnostics consultation
Diagnostics consultation document (PDF 404 KB)
Diagnostics assessment report (PDF 2.96 MB)
Overview (PDF 477 KB)
DAR Addendum (PDF 258 KB)
DAR Erratum (PDF 100 KB)
DAR Comments table and EAG response (PDF 669 KB)
Comments form Supporting document submitted by Microtest Dx (PDF 413 KB)
Specialist committee member list (PDF 88 KB)
Final scope
Final scope (PDF 279 KB)
Final protocol (PDF 490 KB)
Equality impact assessment (PDF 100 KB)